FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback